Efficacy and safety of conventional long acting β2- agonists: systematic review and meta-analysis

Efficacy and safety of conventional long acting β2- agonists: systematic review and meta-analysis

Background: Chronic obstructive pulmonary disease (COPD) is usually considered one of the leading causes of death worldwide, so finding proper therapeutic strategies for this disease is of high importance. In this meta-analysis, we reviewed the existing literature on the efficacy and safety of conve...

Full description

Bibliographic Details
Main Authors:	Reza Karbasi-Afshar, Jafar Aslani, Mostafa Ghanei
Format:	Article
Language:	English
Published:	Babol University of Medical Sciences 2016-04-01
Series:	Caspian Journal of Internal Medicine
Subjects:	beta agonist COPD chronic obstructive pulmonary disease meta analysis
Online Access:	http://caspjim.com/browse.php?a_code=A-10-84-3&slc_lang=en&sid=1

Similar Items

Ultra Long-Acting β-Agonists in Chronic Obstructive Pulmonary Disease
by: Burkes RM, et al.
Published: (2020-12-01)

Pharmacogenetics of β2-Agonists
by: Nobuyuki Hizawa
Published: (2011-01-01)

Long-acting muscarinic antagonists vs. long-acting β 2 agonists in COPD exacerbations: a systematic review and meta-analysis
by: Israel Silva Maia, et al.

Safety of beta-agonists with different duration of action in patients with arterial hypertension and broncho-obstructive diseases
by: Yu A Dolgusheva, et al.
Published: (2015-03-01)

Differences in health care outcomes between postdischarge COPD patients treated with inhaled corticosteroid/long-acting β2-agonist via dry-powder inhalers and pressurized metered-dose inhalers
by: Wittbrodt ET, et al.
Published: (2018-12-01)

Comparative efficacy of long-acting β2-agonists as monotherapy for chronic obstructive pulmonary disease: a network meta-analysis
by: Donohue JF, et al.
Published: (2017-01-01)

Inhalation beta-2-agonists in cardiorespiratory pathology: pro-or anti-inflammatory effects?
by: S. Yu. Nistor, et al.
Published: (2018-12-01)

Efficacy and Safety of Bisoprolol in Patients with Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis
by: Feng Z, et al.
Published: (2023-12-01)

Effect of estrogen receptor β agonists on proliferation and gene expression of ovarian cancer cells
by: Susanne Schüler-Toprak, et al.
Published: (2017-05-01)

β2-Adrenoceptor Agonists in Asthma or Chronic Obstructive Pulmonary Disease and Risk of Parkinson’s Disease: Nested Case-Control Study
by: Paakinaho A, et al.
Published: (2023-06-01)

The use of short-acting bronchodilators in patients with chronic bronchoobstructive pathology at the present stage
by: K. A. Zykov, et al.
Published: (2021-09-01)

The Role of Inhalatory Corticosteroids and Long Acting β2 Agonists in the Treatment of Patients Admitted to Hospital Due to Acute Exacerbations of Chronic Obstructive Pulmonary Disease (Aecopd)
by: Bakir Mehić
Published: (2007-11-01)

Perfil de un paciente con enfermedad obstructiva crónica tratado con la combinación de un agonista β2 adregénico de acción prolongada y un corticoide inhalado en un dispositivo presurizado en la práctica clínica habitual: estudio ARIES
by: Jorge Arencibia-Borrego, et al.
Published: (2023-04-01)

Exacerbations in COPD patients treated with Inhaled Corticosteroids/Long-acting β2 agonists combinations, switching to another combination drugs or inhaler device: A “real – world” study
by: Diego Sangiorgi, et al.
Published: (2017-01-01)

Comparison of Tetropium and β2 Agonist Therapy in Patients with Chronic Obstructive Pulmonary Disease: Systematic Review and Meta-Analysis
by: Hamidreza Dehghan, et al.
Published: (2017-09-01)

Chronic Obstructive Pulmonary Disease Overdiagnosis and Overtreatment: A Meta-Analysis
by: Matteo Fiore, et al.
Published: (2023-11-01)

Patient-reported outcomes of dual bronchodilator fixed-dose combination versus bronchodilator monotherapy in individuals with COPD
by: Strange C, et al.
Published: (2019-06-01)

NEW FIXED COMBINATION OF LONG-ACTING ANTICHOLINERGIC GLYCOPYRRONIUM BROMIDE AND β2-AGONIST OF INDACATEROL: PROSPECTS OF COBD THERAPY
by: S. N. AVDEEV
Published: (2016-12-01)

Beta-adrenergic and M-cholinergic receptor interactions in the pathogenesis of bronchial obstructive pulmonary diseases
by: Anna V. Eremenko, et al.
Published: (2020-10-01)

Risk of all-cause mortality or hospitalization for pneumonia associated with inhaled β2-agonists in patients with asthma, COPD or asthma-COPD overlap
by: Joseph Emil Amegadzie, et al.
Published: (2022-12-01)

p38 MAPK signaling in chronic obstructive pulmonary disease pathogenesis and inhibitor therapeutics
by: Ali Ahmadi, et al.
Published: (2023-11-01)

Optimal Bronchodilation for COPD Patients: Are All Long-Acting β2-Agonist/Long-Acting Muscarinic Antagonists the Same?
by: Marc Miravitlles, M.D., et al.
Published: (2018-07-01)

COPD: What the anaesthetist should know
by: M. L. Wong
Published: (2016-05-01)

Comparative Study on the effectiveness of Glycopyrrolate/Formoterol versus Tiotropium/Formoterol in patients with Chronic Obstructive Pulmonary Disease
by: Nalini Jayanthi, et al.
Published: (2022-08-01)

LABA in patients with stage I COPD and mild sleep apnea syndrome: a pilot study
by: Kopitovic Ivan, et al.
Published: (2011-02-01)

Where current pharmacological therapies fall short in COPD: symptom control is not enough
by: N. Roche
Published: (2007-09-01)

Extrafine triple therapy delays COPD clinically important deterioration vs ICS/LABA, LAMA, or LABA/LAMA
by: Singh D, et al.
Published: (2019-02-01)

Clinical Relevance of the Anti-inflammatory Effects of Roflumilast on Human Bronchus: Potentiation by a Long-Acting Beta-2-Agonist
by: Hélène Salvator, et al.
Published: (2020-12-01)

Management of chronic obstructive pulmonary disease: Insights into patient profile – Use of inhaled corticosteroids/long-acting β2-Agonists or long-acting β2-agonists/long-acting muscarinic antagonists
by: Nevin Kishore, et al.
Published: (2020-01-01)

Prevalence of overuse of short-acting beta-2 agonists (SABA) and associated factors among patients with asthma in Germany
by: Heinrich Worth, et al.
Published: (2021-04-01)

The Role of Glucagon-Like Peptide-1 Receptor Agonists in Chronic Obstructive Pulmonary Disease
by: Wang W, et al.
Published: (2023-02-01)

Beta-blocker therapy in patients with COPD: a systematic literature review and meta-analysis with multiple treatment comparison
by: Claudia Gulea, et al.
Published: (2021-02-01)

Β2-agonist in patients with chronic obstructive pulmonary disease
by: N. N. Mescheryakova
Published: (2014-12-01)

Overuse of Short-Acting Beta-2 Agonists (SABAs) in Elite Athletes: Hypotheses to Explain It
by: Nicolas Vertadier, et al.
Published: (2022-03-01)

Healthcare costs associated with short-acting β2-agonists in asthma: observational UK SABINA study
by: Darush Attar-Zadeh, et al.
Published: (2023-09-01)

Transdermal Tulobuterol Patch, a Long-Acting β2-Agonist
by: Gen Tamura, et al.
Published: (2012-01-01)

Assessment of the Association of COPD and Asthma with In-Hospital Mortality in Patients with COVID-19. A Systematic Review, Meta-Analysis, and Meta-Regression Analysis
by: Felix M. Reyes, et al.
Published: (2021-05-01)

Risk Factors of Local Oropharyngeal and Laryngeal Adverse Effects from Use of Single Inhaled Corticosteroids and Long-Acting Beta-Agonists
by: Nobuyuki Horita, et al.
Published: (2012-01-01)

Differential pharmacology and clinical utility of long-acting bronchodilators in COPD – focus on olodaterol
by: Matera MG, et al.
Published: (2015-12-01)

Respiratory symptoms (COPD Assessment Test and modified Medical Research Council dyspnea scores) and GOLD-ABCD COPD classification: the LASSYC study
by: Maria Montes de Oca, et al.
Published: (2021-11-01)